Veliparib for the treatment of solid malignancies.

Objective: Veliparib is a poly adenosine diphosphate ribose polymerase (PARP) -1 and -2 inhibitor with chemo-sensitizing and anticancer activities that has shown promising results in early-phase trials. The aim of this comprehensive review is to summarise the profile of veliparib and to provide an overview of its early clinical investigations.

Data Sources: Details of all the completed trials evaluating the profile of veliparib were identified from ClinicalTrials.